Headlines
Below is a list clinical trials supported by INNODIA that are currently recruiting or will be recruiting in the near future, and for which you can submit an request using the contact email address displayed for each study.
FrexalimAB in Preservation of Endogenous insULIN Secretion (FABULINUS)
The goal of this study is to determine if treatment with Frexalimab preserves endogenous insulin secretion compared to placebo in adults and adolescents on top of insulin therapy.
THIS CLINICAL TRIAL IS RECRUITING
A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients (STRIDE)
The goal of this study is to determine if treatment with TCD601 improves beta-cell function in adults recently diagnosed with type 1 diabetes compared to placebo.
THIS CLINICAL TRIAL WILL RECRUIT OVER THE COMING MONTHS
Clinical Trials open to enrolment
Ver-A-T1D
An INNODIA project (iwww.innodia.eu)
trial with Verapamil.
This known blood pressure lowering drug has been shown recently to protect and strengthen beta cells and slowing down beta cell destruction in T1D.
The trial had included 120 patients aged between 18 and 45 years, taking tablets for 1 year.
Running Clinical trials closed to enrolment
Below is a list of previously launched clinical trials for which patient recruitment has now been completed.
They still in follow-up.
MELD-ATG
An INNODIA project (iwww.innodia.eu) trial
RECRUITMENT COMPLETED – AWAITING RESULTS - STILL IN FOLLOW-UP
The drug ATG (Anti Thymocyte Globulin) provided by our partner Sanofi, tested over 12 months in adolescents to adults (5-25 years of age, n=114).
ATG, given once in a two days infusion regimen, is a drug recently shown to be able to keep the balance between attacking and regulating cells within the immune system, and thereby helping to preserve insulin secretion.
Defining the minimal effective dose of ATG treatment is one aim of the study.
Impact
An INNODIA project (iwww.innodia.eu) trial
RECRUITMENT COMPLETED – AWAITING RESULTS - STILL IN FOLLOW-UP
The IMPACT trial investigates a very specific and novel immunotherapy called Imotopes™ that has the potential to stop the progression of type 1 diabetes.
The treatment was already administered in a first clinical trial and showed a good safety profile.
This new study is now testing two doses of Imotope™ in newly diagnosed adult (18-44 years) patients to evaluate efficacy on stopping the loss of the beta cell.
Participants are receiving 6 initial administrations of the treatment and 1 additional boost administration. Patients will be followed for up to 2 years with a primary evaluation after 1 year.
The recruitment in the study is now completed and the first results are expected in Spring 2024.
CFZ533 - ISCALIMAB
An INNODIA project (iwww.innodia.eu) trial
RECRUITMENT COMPLETED - STILL IN FOLLOW-UP
INNODIA is collaborating with Novartis Pharmaceuticals on a study to evaluate the safety of the investigational drug CFZ533 (Iscalimab) in young adult and pediatric patients with recent onset type 1 diabetes. The study will evaluate whether CFZ533 can protect the remaining pancreatic beta cells.
The study is now closed to new enrollment.
Innodia can help you set up your clinical trial
Are you wanting to design, execute and run a clinical study in type 1 diabetes in a given time?
By mobilising its Network of accredited sites and providing ongoing, high-performance support throughout each clinical trial, INNODIA is your preferred partner for testing your disease-modifying therapy.
